Galmed Pharmaceuticals (GLMD) FCF Payout Ratio Growth (1y) (2014 - 2023)
Galmed Pharmaceuticals (GLMD) FCF Payout Ratio Growth (1y) (2014 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 68.88% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -31.89% |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 31.87% |
| Mar 31, 2020 | 79.16% |
| Sep 30, 2019 | 117.68% |
| Jun 30, 2019 | 249.34% |
| Mar 31, 2019 | -1,187.91% |
| Sep 30, 2018 | -3,556.85% |
| Jun 30, 2018 | -7,768.26% |
| Mar 31, 2018 | -76.93% |
| Sep 30, 2017 | 76.47% |
| Jun 30, 2017 | -167.17% |
| Mar 31, 2017 | 57.24% |
| Sep 30, 2016 | -200.48% |
| Jun 30, 2016 | 101.46% |
| Mar 31, 2016 | 3.30% |
| Sep 30, 2015 | 26.20% |
| Jun 30, 2015 | -414.11% |
| Mar 31, 2015 | 94.23% |
| Sep 30, 2014 | 726.80% |
| Jun 30, 2014 | -0.53% |
| Mar 31, 2014 | -3,010.77% |